Patents Assigned to Targeted Molecular Diagnostics
  • Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
    Patent number: 7862995
    Abstract: The present invention relates to a panel of targeted therapy markers that can be used in assessing a particular subject's sensitivity to various therapeutic agents and cancer treatments as a means of prognosticating whether a treatment or use of a particular therapeutic agent will result in a clinically positive outcome. Cellular receptors, ligands to those receptors and molecules involved in the programmed cell death pathway are examples of targeted therapy markers that might be used in the present invention.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: January 4, 2011
    Assignee: Targeted Molecular Diagnostics
    Inventors: Sarah S. Bacus, Jason Hill
  • BIVALENT ErbB LIGAND BINDING MOLECULES AND METHODS FOR THEIR PREPARATION AND USE
    Publication number: 20090318346
    Abstract: A new bivalent ErbB-based ligand binding molecule is disclosed along with its method of preparation and use. The binding molecule can be a protein expressed from a recombinant DNA molecule. The protein can contain two extracellular domains of an ErbB receptor that both bind to ErbB receptor ligands. These binding molecules act as traps to bind and sequester ligands, thus making them unavailable for binding to cellular ErbB receptors.
    Type: Application
    Filed: February 8, 2007
    Publication date: December 24, 2009
    Applicants: Targeted Molecular Diagnostics, Yeda Research and Development Co., Ltd.
    Inventors: Sarah S. Bacus, Jason E. Hill, Josef Yarden, Bose S. Kochupurakkal